U.K. Says Ireland Drug Supply at Risk in No-Deal Scenario
(Bloomberg) -- U.K. Health Secretary Matt Hancock said a no-deal Brexit could lead to drug shortages in the Republic of Ireland and on mainland Europe, as negotiations continue with the European Union over securing a withdrawal agreement acceptable to the British parliament.
“There are more drugs that flow from us to them: you would have thought that nobody on the other side would have wanted to have a blockage,” Hancock told an LBC radio phone-in show Monday, referring to continental Europe. He was answering a question about drug shortages if ports face delays in processing goods should Britain leave the EU without a deal at the end of the month.
“Most of the Republic of Ireland's drugs come through the same route as they come to the U.K. so if there were a blockage, the blockage would not only be stopping drugs from going from the U.K. to the France and the rest of Europe, as well as obviously to the U.K., but also the drugs supply to Ireland,” Hancock said.
With just 25 days to go until Britain is set to leave the EU, time is running out for Prime Minister Theresa May to secure a deal that's acceptable to politicians at home. In the event of no-deal leading to blockages at Dover and Calais lasting longer than six weeks, other ferry routes would be used, Hancock said. He has also awarded a contract to delivery company DHL to fly medical supplies to and from Birmingham, central England and Maastricht in the Netherlands.
To contact the reporter on this story: Kitty Donaldson in London at kdonaldson1@bloomberg.net
To contact the editors responsible for this story: Tim Ross at tross54@bloomberg.net, Alex Morales, Stuart Biggs
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.